Akebia Therapeutics
AKBA
$1.34
Share price
0.75%
Change (1 day)
47.25%
Change (1 year)
Categories
P/S ratio for Akebia Therapeutics (AKBA)
P/S ratio as of April 2024 (TTM): 1.44
According to Akebia Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.44065. At the end of 2023 the company had a P/S ratio of 1.20.
P/S ratio history for Akebia Therapeutics from 2014 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 1.20 | 229.93% |
| 2022 | 0.3636 | -80.36% |
| 2021 | 1.85 | 35.09% |
| 2020 | 1.37 | -40.3% |
| 2019 | 2.30 | -26.23% |
| 2018 | 3.11 | -21.21% |
| 2017 | 3.95 | -98.48% |
| 2016 | 260 | |
| 2015 | N/A | |
| 2014 | N/A |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.79 | 162.79% | 🇺🇸 USA |
 Novartis NVS | 4.01 | 178.21% | 🇨🇭 Switzerland |
 Amgen AMGN | 5.14 | 256.57% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | 2.69 | 86.68% | 🇺🇸 USA |